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Background—Pulmonary arterial hypertension (PAH) is a severe and progressive disease, a
hallmark of which is pulmonary vascular remodeling. Nicotinamide phosphoribosyltransferase
(NAMPT), is a cytozyme which regulates intracellular NAD levels and cellular redox state,
regulates histone deacetylases, promotes cell proliferation and inhibits apoptosis. We hypothesized
that NAMPT promotes pulmonary vascular remodeling, and that inhibition of NAMPT could
attenuate pulmonary hypertension.

Author Manuscript

Methods—Plasma and mRNA and protein levels of NAMPT were measured in the lungs and
isolated pulmonary artery endothelial cells (PAECs) from PAH patients, as well as in lungs of
rodent models of pulmonary hypertension (PH). Nampt+/− mice were exposed 10% hypoxia and
room air for 4 weeks and the preventive and therapeutic effects of NAMPT inhibition were tested
in the monocrotaline and Sugen-hypoxia models of PH. The effects on NAMPT activity on
proliferation, migration, apoptosis and calcium signaling were tested in human pulmonary artery
smooth muscle cell (hPASMC).
Results—Plasma and mRNA and protein levels of NAMPT were increased in the lungs and
isolated pulmonary artery endothelial cells (PAECs) from PAH patients, as well as in lungs of
rodent models of pulmonary hypertension (PH). Nampt+/− mice were protected from hypoxiamediated PH. NAMPT activity promoted human pulmonary artery smooth muscle cell (hPASMC)
proliferation via a paracrine effect. In addition, recombinant NAMPT stimulated hPASMC
proliferation via enhancement of store-operated calcium entry by enhancing expression of Orai2
and STIM2. Finally, inhibition of NAMPT activity attenuated monocrotaline and Sugen hypoxia
induced PH in rats.

Author Manuscript

Conclusions—Our data provide evidence that NAMPT plays a role in pulmonary vascular
remodeling and its inhibition could be a potential therapeutic target for PAH.
Keywords
Pulmonary hypertension; NAMPT; pulmonary vascular remodeling

Subject Terms
Pulmonary Biology; Vascular Biology; Smooth Muscle Proliferation and Differentiation
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Pulmonary arterial hypertension (PAH) is a progressive disease caused by functional and
structural changes in the pulmonary vasculature, which lead to increased pulmonary vascular
resistance and, eventually right ventricular failure and death. PAH is characterized by
vasoconstriction, in-situ thrombosis, vascular inflammation and pulmonary artery smooth
muscle cell (PASMC) and pulmonary artery endothelial cell (PAEC) proliferation and
apoptosis resistance1. PAEC dysfunction and injury are believed to play a critical role in the
pathogenesis of the disease and can trigger PASMC proliferation and migration through
activation growth factors or disruption of cell survival mediators2, 3. Although important
progress has been made in recent years, the precise cellular and molecular basis of
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pulmonary vascular remodeling in PAH continues to evolve and the discovery of therapeutic
targets that attenuate vascular remodeling is still ongoing.

Author Manuscript

Nicotinamide phosphoribosyltransferase (NAMPT), also called visfatin and pre-B cell
colony-enhancing factor (PBEF), was first characterized as a cytokine acting on early Blineage precursor cells, and is a pleiotropic protein with extracellular proinflammatory
cytokine-like activity and intracellular enzymatic activity as a
phosphoribosyltransferase4–10. It has been demonstrated as the rate-limiting component of
the mammalian NAD biosynthesis pathway from nicotinamide11. NAMPT activity has been
linked to several processes involving cellular adaptation to stress responses. These include
resistance to senescence, apoptosis and increase in cell proliferation and regulation of
cellular redox state6–8, 12, 13. At the pathological level NAMPT promotes inflammatory
responses by increasing inflammatory cell survival and increasing pro-inflammatory
cytokine production8, 14–16. NAMPT is also up regulated in many types of malignancies
where it promotes cell survival, proliferation and resistance to chemotherapeutic
agents7, 17–21. In vascular cells NAMPT promotes endothelial cell survival and angiogenic
activity as well as smooth muscle cell survival10, 13, 22–24. We therefore hypothesized that
NAMPT may play an important role in PAH pathobiology by promoting pulmonary vascular
remodeling during pulmonary hypertension development, and that inhibition of NAMPT
could attenuate experimental pulmonary hypertension.

Methods
Human Lung Tissues, Human PAECs and Human PASMCs (hPASMCs)

Author Manuscript

Approval for the collection of plasma and the use of human lung tissues and cells was
granted by Institutional Review Boards of participating centers. Plasma samples were
obtained from 103 patients with PAH defined by the 2013 Nice classification25 and 53
controls including patients with hypothyroidism, osteoporosis, nephrolithiasis, diabetes
mellitus, osteoarthritis and hypertension. De-identified human explanted peripheral lung
tissues and PAECS used in this study were from four control subjects (2 unsuitable organ
donors and 2 chronic obstructive pulmonary disease patients without PH) and patients with
idiopathic PAH (IPAH, 4 patients diagnosed on the basis of National Institutes of Health
PAH Registry criteria) obtained at the Cleveland Clinic Foundation. PAECs were isolated as
previously described26. In addition, a primary hPASMC and hPAEC cell lines from Lonza
(CC-2581 and CC-2530) were used for cell transfection and proliferation assays. Cells were
cultured at 37°C in their complete medium with 10% fetal bovine serum and studied at
passages 5 to 8.

Author Manuscript

Reagents, Pharmacologic Inhibitors and Antibodies
The information for reagents, pharmacologic inhibitors and antibodies is provided in the
supplementary Materials and Methods.
Western Blotting
Solubilized protein lysates isolated from lung tissues and cells were used to detect NAMPT,
STIM2, ORAI2 and β-actin. Cells were lysed in a modified radioimmunoprecipitation assay
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(mRIPA) lysis buffer with a protease and phosphatase inhibitor cocktail (Sigma Aldrich, St.
Louis, MO), and protein quantification and Western blot analysis were performed according
to standard procedures.
RNA Isolation and Real-time PCR
Total RNA from lung tissues or cells was isolated using the RNeasy Plus Mini Kit
(Cat.#74134, Qiagen). Two micrograms of purified RNA was attenuate transcribed to singlestranded cDNA using the Taqman RNA attenuate transcription kit (Cat.#N8080234, Applied
Biosystems, Inc. [ABI]). Real-time PCR was performed on an ABI 7900HT machine.
Specific Taqman quantitative real-time PCR assays were ordered from ABI (specific assay
IDs available upon request). The relative mRNA expression levels were normalized to the
expression of a housekeeping gene, glucose-6-phosphate dehydrogenase (G6PDH), and
determined by calculating the ΔΔCt value, as detailed in the manufacturer’s guidelines.

Author Manuscript

Mouse PASMC isolation

Author Manuscript

A mixture of 5 ml of medium 199 (M199) growth medium containing 5 g/l low-meltingpoint agarose type VII (Sigma, St. Louis, MO), 5 g/l iron beads (diameter <10 μM; Sigma),
and antibiotics (penicillin and streptomycin) was slowly injected over a period of 60 seconds
through the RV, thereby perfusing the PA. M199 growth medium (1 ml) containing 5 g/l
agarose type VII was injected in airways through the trachea. The lungs were plunged in
cold PBS to cause the agarose to gel. Because of the rapidly solidifying nature of the agarose
and the size of the iron particles, the likelihood of traversing the capillary space is
minimized. All the lobes were then isolated and finely minced in a Petri dish. The tissue was
further disrupted by passing through a 16-gauge followed by an 18-gauge needle
approximately five times. The suspension was then mixed in M199 growth medium
containing 80 U/ml type IV collagenase (Sigma) and incubated at 37°C for 90 min. With the
use of a magnetic column (Invitrogen), the arteries or arterial tissues containing the iron
beads were collected. The supernatant was aspirated and the arteries were washed and
suspended in 5 ml M199 containing 20% FBS. Aliquots of the suspension were transferred
to T25 culture flasks. Cells from the hypoxic group were incubated at 3% O2, whereas cells
from the normoxic control were cultured in air. Smooth muscle cell purity was determined
by immunostaining with smooth muscle specific α-actin antibody.
Cell Proliferation Assays

Author Manuscript

Cell proliferation was determined using either a 5-bromo-2′-deoxyuridine (BrdU)
incorporation assay or cell counting. BrdU assays (QIA58, Calbiochem, San Diego, CA)
were performed in a 96-well format according to manufacturer’s instructions, using starting
cell densities of 4000 cells/well. For cell counting, cells were trypsinized and resuspended
after experimental procedures; densities were counted with a TC10™ automated cell counter
(Bio-Rad). FBS or PDGF was used as positive controls.
Overexpressing NAMPT in hPASMCs and hPAECs
A human wild-type NAMPT expression sequence was cloned downstream of the ubiquitin
promoter in a third generation lentiviral plasmid. Separately, a control plasmid was
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generated by cloning a GFP expression sequence in the same position. Co-transfection of
either control-GFP or NAMPT-expressing constructs with three other packaging plasmids in
HEK 293FT cells produced lentivirus capable of expressing either GFP or NAMPT. Viral
concentration was determined by qPCR using primers spanning the HIV 5′LTR region.
hPASMCs and hPAECs were infected with control or NAMPT virus at an MOI of 5 for
experiments performed 72 hours later.
Plasma and cell culture medium NAMPT measurement
Plasma NAMPT levels were measured using Bio-Plex Pro Human Diabetes Visfatin Set
(Bio-Rad, cat.#171-B7012M). NAMPT secreted from hPAECs during the culture was
measured using a Nampt (Visfatin/PBEF) (human) ELISA Kit (Adipogen,
cat.#AG-45A-0006YEK-KI01).

Author Manuscript

[Ca2+]cyt Measurement
[Ca2+]cyt was measured in PASMC loaded with fura-2 (4μM) in a Nikon digital fluorescent
imaging system. Cells were loaded with 4 μM fura-2 acetoxymethyl ester (fura-2/AM) for
60 min at 25°C and [Ca2+]cyt was measured using a ratiometric method at 32°C.
Cyclepiazonic acid (CPA, a specific Ca2+-ATPase inhibitor) was used to induce storeoperated calcium entry (SOCE).
Transfection of Small Interfering RNA (siRNA) in hPASMCs

Author Manuscript

Using Lipofectamine™ RNAiMAX Reagent (Invitrogen, cat.# 13778-150), hPASMCs were
transfected with NAMPT siRNA (L-000458-00), STIM2 siRNA (L-013166-01-0005),
ORAI2 siRNA (L-015012-00) or scrambled siRNA (D-001810-02), which were purchased
from Dharmacon (Thermo Fisher Scientific, Lafayette, CO, USA) according to the
manufacturer’s protocol.
Animal Models of Pulmonary Hypertension and Hemodynamic Measurements

Author Manuscript

All experiments were approved by the Ethics and Animal Care Committee of the University
of Illinois at Chicago. Three rodent models of PH were used in this study. They included a
mouse model of hypoxia-induced PH, a rat model of monocrotaline (MCT)-induced PH and
a rat model of Sugen-hypoxia induced severe PH. Nampt−/− mice exhibit embryonic lethality
thus Nampt+/− mice were used in this study. Male mice (8-week old Nampt−/− mice in
C57BL/6 background and their WT siblings) were exposed to hypoxia (10% O2) in a
ventilated chamber for four weeks. Male Sprague-Dawley rats (190–200 g) were used for
the MCT and Sugen-hypoxia induced PH studies. In the MCT-induced PH model, MCT was
dissolved in 0.5N HCl to 200 mg/ml, neutralized to pH 7.4 with 0.5N NaOH, and then
diluted with sterile water to 60 mg/ml. One dose of MCT (60 mg/kg body weight) was
subcutaneously injected to rats. Control rats were injected with the equivalent volume of
dissolvent solution according to their weights. Food and water were provided ad libitum and
the rats are checked once per day. For the prevention experiment, FK866 (2.5 mg/kg) was
started in day 2 after the MCT injection and continued for two weeks; for the therapeutic
experiment, FK866 (2.5mg/kg every 48 hours) was started day 14 after the MCT injection
and continued for two weeks. Our historical data shows that rats in day 14 after MCT
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injection develop pulmonary hypertension as demonstrated by significantly increased RVSP
and RVH (Supplemental Figure S1). Each group included 6 to 8 rats. In the Sugen-hypoxia
PH model, one dose of Sugen (20 mg/kg) was given subcutaneously at the first day of
hypoxia exposure (10% O2). After three-week chronic hypoxia exposure, the rats were
placed back to room air. FK866 (2.5 mg/kg every 48 hours) was then started two weeks after
reoxygenation and continued for three weeks. Each group included 10 to 12 rats.
Hemodynamic data after two-week reoxygenation indicates that rats develop significant PH
at this time point (Supplemental Figure S2). Right ventricular systolic pressure (RVSP) was
determined by right heart catheterization using a Millar pressure transducer catheter. A
weight ratio of the right ventricle divided by the sum of left ventricle and septum (RV/(LV
+S)) was measured to determine the extent of right ventricular hypertrophy (RVH). The RV
contractility index was calculated as (dp/dt)max/instantaneous RV pressuremax, as previously
described.27 Pulmonary artery remodeling was assessed using Aperio ImageScope software
(version 11) after lungs were stained with hematoxylin and eosin (H&E). A minimum of 10
microscopic fields were examined for each slide. Approximately twenty muscular arteries
with diameters (D) 50–100 μm or D < 50 μm per lung section were outlined and measured.
Vessel remodeling was calculated as ((external vessel area – internal vessel area) / external
vessel area), as previously described28. Occlusive pulmonary arteries were counted from
H&E stained lung slides from each group.

Author Manuscript

Statistical Analysis

Author Manuscript

Statistical analysis of experimental data was performed using GraphPad Prism 5.1
(GraphPad Software, Inc., La Jolla, CA). Results are expressed as mean ± standard error of
mean (SEM), except where noted, from at least three experiments. Student t - test and
ANOVA were used to compare two and three groups, respectively except for the comparison
of NAMPT plasma levels between control and PAH subjects where a Mann-Whitney test
was used. A P < 0.05 was considered statistically significant.

Results
NAMPT is Up-regulated in Patients with PAH and in Experimental Rodent PH Models

Author Manuscript

Plasma NAMPT levels were significantly elevated in patients with PAH (n=103, median
[IQR] 3197 [1493–7280]) when compared to controls (n=53, median [IQR] 1686 [990–
2608]; p<0.001 by Mann-Whitney test, Figure 1A, Supplemental Table 1). mRNA and
protein levels of NAMPT were significantly elevated in the lungs and PAECs from patients
with PAH when compared to control subjects (Figures 1B–1F and supplemental Figure S3).
Pulmonary artery smooth muscle cells isolated from PAH patients did not express higher
levels of NAMPT, compared to controls (Supplemental Figure S4).
A similar pattern was found in different rodent models of PH including a mouse model of
hypoxia-mediated pulmonary hypertension (HPH, 10% hypoxia for 4 weeks, Figure 2A), a
rat model of monocrotaline-induced PH (2 weeks after administration of monocrotaline [60
mg/kg bw, SQ], Figure 2B) and a rat model of the VEGF receptor blocker sugen plus
hypoxia mediated PH (sugen [20 mg/kg bw, SQ] followed by 10% hypoxia for 3 weeks and
normoxia for 3 weeks, Figure 2C). In addition, the NAMPT expression profiles in lung
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tissues from these different rodent models of PH were examined using immunofluorescence
staining. As shown in Supplemental Figures S5–6, NAMPT expression in experimental PH
appears to increase in the pulmonary vasculature mainly in PAECs and the adventitia, but
not in the media, as well as in airway and alveolar epithelial cells. Alveolar macrophages
also express NAMPT, especially in the rat model of PH mediated by monocrotaline, as
demonstrated by CD68 immunostaining (data not shown).
In aggregate, these results suggest that NAMPT may play a role in the development of
pulmonary hypertension.
NAMPT Heterozygous (Nampt+/−) Mice are Protected from HPH

Author Manuscript

To examine the effect of NAMPT on the development of pulmonary hypertension, Nampt+/−
mice and their WT siblings in a C57BL6 background were exposed to 10% hypoxia for four
weeks. Compared to WT siblings, Nampt+/− mice exhibited significantly lower baseline
levels of NAMPT and NAD in lung tissue homogenates (Supplemental Figure S7). After
four-week hypoxia exposure, Nampt+/− mice displayed significantly lower right ventricular
systolic pressure (RVSP, Figure 3A), decreased RVH (right ventricular hypertrophy, assessed
by RV/(LV+S) ratio, Figure 3B), and less severe pulmonary vascular remodeling in response
to hypoxia when compared to control mice (Figure 3C–E). Furthermore, PASMCs isolated
from Nampt+/− mice were less proliferative compared to WT mice as demonstrated by BrdU
incorporation and cell counting (Figure 3F–3G). Similarly, silencing NAMPT via siRNA
attenuated complete medium, hypoxia or PDGF-mediated hPASMC proliferation
(Supplemental Figure S8).
NAMPT activity promotes PASMC proliferation

Author Manuscript
Author Manuscript

In addition to increased expression, PAECs isolated from patients with PAH secreted more
NAMPT in culture media than control cells (Figure 4A). Further, conditioned media from
PAECs isolated from PAH patients significantly promoted hPASMC proliferation. This
effect was significantly attenuated by the NAMPT enzymatic activity inhibitor FK86621
(Figure 4B). Lentivirus-mediated NAMPT overexpression promoted both hPAECs and
hPASMC proliferation (Figure 4C–I). When compared to control cells, hPAECs
overexpressing NAMPT secreted more NAMPT and conditioned media from these cells
stimulated more hPASMC proliferation (Figure 4J). These effects were attenuated by FK866
(Figure 4F, 4I, 4J). Finally, recombinant NAMPT protein (rNAMPT) promoted hPASMC
proliferation in a dose-dependent manner (an effect that was attenuated by FK866, Figure
4K) and enhanced hPASMC migration (an effect that was attenuated by FK866,
Supplemental Figure S9). Taken together these data suggest that NAMPT promotes
hPASMC proliferation and migration in an autocrine and paracrine manner.
Inhibition of NAMPT activity promotes PASMC apoptosis
Since NAMPT promotes resistance to apoptosis6–8 and resistance to apoptosis is a major
contributor to the pathobiology of PAH, we tested whether inhibition of NAMPT activity
would promote PASMC apoptosis. As shown in Supplemental Figure S10, treatment with
FK866 induced hPASMCs apoptosis. Further, treatment with rNAMPT protected PASMCs
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from H2O2 induced apoptosis, an effect that was attenuated by concomitant FK866
treatment.
NAMPT Enhances Store-Operated Calcium Entry (SOCE) in PASMCs
NAMPT activity promotes inflammatory responses including the expression of
inflammatory cytokines. For instance, NAMPT derived NAD promotes TNF-α synthesis by
activated immune cells29. Since inflammatory pathways, particularly the cytokine TNF-α,
have been shown to promote SOCE30, 31, we hypothesized that NAMPT-induced PASMC
proliferation would be mediated by enhancement of SOCE. To test this hypothesis, we
treated PASMCs with rNAMPT (20 μg/ml) for 48 hours. [Ca2+]cyt was measured in
PASMCs loaded with fura-2/AM (4 μM) using a fluorescence microscope, and
cyclopiazonic acid (CPA) was used to induce SOCE. After 48 hours rNAMPT treatment
significantly enhanced CPA-mediated SOCE in PASMCs (Figure 5A).

Author Manuscript

ORAI calcium release-activated calcium modulator 2 (Orai2) and stromal interaction
molecule 2 (STIM2) are up regulated in PASMCs from patients with PAH and contribute to
enhanced store-operated calcium entry and to the transition of these cells from a contractile
to proliferative phenotype32. Given these findings we tested whether NAMPT activity would
enhance SOCE via up regulation of Orai2 and STIM2. NAMPT treatment increased the
expression of both Orai2 and STIM2 (Figure 5B–E) but did not change the expression of
Orai1 and STIM1 (data not shown). Inhibition of NAMPT via FK866 attenuated NAMPTmediated STIM2 and ORAI2 upregulation (Figure 5B–E) and silencing of either Orai2 or
STIM2 attenuated NAMPT-induced hPASMC proliferation (Figure 5F). This data suggests
that SOCE is required for the proliferative effect of NAMPT in PASMCs.

Author Manuscript

Finally, the effect of NAMPT on the L-type calcium channel mediated signaling was also
examined. Blockage of L-type channels with verapamil did not affect rNAMPT mediated
hPASMC proliferation (Supplemental Figure S11).
Inhibition of NAMPT by FK866 prevents and attenuates monocrotaline-induced PH in rats

Author Manuscript

To examine the potential therapeutic role of NAMPT inhibition in PH, we evaluated the
effect of FK866 in monocrotaline (MCT)-induced PH model in rats. In PH prevention
experiments FK866 (2.5mg/kg every 48 hours IP) or vehicle were given to rats (n = 6–8
animals per group), starting one day after subcutaneous injection of MCT (60 mg/kg bw)
and in PH reversal experiments FK866 (2.5mg/kg every 48 hours IP) or vehicle were given
to rats (n = 6–8 animals per group), starting fourteen days after MCT injection (60 mg/kg
bw). When compared to vehicle-treated rats, treatment with FK866 prevented (Figure 6) and
also attenuated (Figure 7) the development of PH. In both experiments, FK866 treatment
significantly reduced the PH assessed by the RVSP as well as RVH, RV contractility index
and the degree of pulmonary artery muscularization. Furthermore, FK866 treatment
decreased PASMCs proliferation, as demonstrated by PCNA and smooth muscle actin
double immunostaining of lung tissues (Supplemental Figure S12).
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Inhibition of NAMPT by FK866 attenuates Sugen-hypoxia mediated PH in rats

Author Manuscript

The rat model of PH mediated by Sugen and hypoxia induces severe pulmonary vascular
remodeling characterized by obliterative pulmonary vascular lesions with neointima
formation in distal pulmonary arteries. We assessed if NAMPT inhibition by FK866 (2.5
mg/kg every 48 for three weeks) after rats (n= 8–12 per treatment group) were given sugen
(20 mg/kg, SQ, once), exposed to chronic hypoxia for 3 weeks, and then kept in normoxia
for another two weeks. When compared to controls, FK866 treatment attenuated the
development of PH assessed by changes in RVSP, RVH and RV contractility index as well as
the development of medial hypertrophy and neointima formation (Figure 8). FK866
treatment also decreased cell proliferation in obliterative lesions (Supplemental Figure S13).
Taken together with the results from the MCT studies, these data suggest that NAMPT
inhibition is a novel therapeutic target in PAH.

Author Manuscript

Discussion

Author Manuscript

Here we show that NAMPT is upregulated in the plasma, lungs and PAECs isolated from
patients with PAH, and in different rodent models of PH. PAECs from patients with PAH are
more proliferative and secrete more NAMPT which promotes PASMC proliferation in a
paracrine fashion via calcium signaling. We also show that NAMPT contributes to
pulmonary vascular remodeling in vivo and that pharmacologic inhibition of NAMPT
activity attenuates experimental PH. NAMPT is a multifunctional protein with extracellular
proinflammatory cytokine-like activity as well as intracellular enzymatic activity as a
phosphoribosyltransferase, which regulates NAD levels4. As such, NAMPT regulates the
activity of NAD-dependent enzymes, such as sirtuins and poly(ADP-ribose) polymerases,
and functions as a master regulator of cellular metabolism, mitochondrial biogenesis and
adaptive and maladaptive responses to cellular stress10.

Author Manuscript

There are several potential mechanisms for the upregulation of NAMPT in patients with
IPAH and in experimental models of PH. As major mediators contributing to PAH
pathobiology, hypoxia, upregulation of growth factors and inflammatory pathways can also
influence NAMPT expression. The NAMPT promoter has hypoxia-inducible factor
responsive elements that affect the transcriptional regulation of NAMPT33, 34. The NAMPT
promoter also contains binding sites for NF-1, AP-1, and NF-κB and tumor necrosis factor
α (TNFα), IL-1β and IL-6 increase NAMPT expression9. Epigenetic regulation of NAMPT
expression via micro RNAs has been demonstrated in PAECs35, colorectal cancer cell
lines36, hepatocytes37 and TZM-bl HeLa cell lines38. It is possible that similar effects could
occur in the context of PAH. Further studies in this area are warranted. NAMPT levels are
also increased and correlate with disease severity in metabolic syndrome and diabetes39–41
as well as coronary artery disease42. This suggests that NAMPT should be studied as a
prognostic biomarker in PAH.
Uncontrolled PASMC proliferation and resistance to apoptosis are major contributors to the
pathobiology of PAH. Our results demonstrate that NAMPT promotes PASMC proliferation
in a dose-dependent manner, suggesting that it plays a significant role in the pulmonary
vascular remodeling associated with PAH. Ca2+ signaling in PASMCs promotes vascular
remodeling through its stimulatory effect on PASMC proliferation and migration. Previous
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studies have shown that PASMC from idiopathic PAH patients exhibit enhanced SOCE
when compared to control PASMCs and that SOCE contributes to PASMC
proliferation32, 43–47. Specifically, STIM2 and Orai2 both contribute to SOCE and are
upregulated in PASMCs from patients with idiopathic PAH and from animals with
experimental pulmonary hypertension in comparison to controls ultimately contributing to
the transition of these cells from a contractile to proliferative phenotype32, 47. We show that
NAMPT enhances SOCE in PASMCs by increasing the expression of STIM2 and Orai2 and
that inhibition of NAMPT activity decreases the expression of these two proteins. In line
with these observations, Ye and colleagues have shown that NAMPT knockdown blunted
thrombin-mediated increases in Ca2+ entry in human PAEC48. We speculate that NAMPT
activity could enhance SOCE by upregulating inflammatory pathways as shown in human
aortic smooth muscle cells49. Inflammatory cytokines such as TNF-α have been known to
increase agonist-induced [Ca2+]i response and contractility in airway smooth muscle
cells31, 50–52 as well as to increase SOCE in these cells30, 31, 53. Furthermore, LPS-induced
activation of both the NF-κB and p38 MAPK signaling pathways induce STIM1 expression
in PAECs54. Interestingly, by increasing NAD levels, NAMPT promotes TNF synthesis via
regulation of SIRT6 activity29, 55. The extracellular cytokine-like activity of NAMPT could
also potentially activate NF-κB signaling and further enhance SOCE56, 57.
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The paracrine effects of NAMPT have been demonstrated in other studies. Pilai and
colleagues58 showed that cardiac-specific overexpressing NAMPT transgenic mice
spontaneously developed cardiac hypertrophy and that treatment of cardiomyocytes with
recombinant NAMPT induced cardiomyocyte hypertrophy. Yoon and colleagues59
demonstrated that deacetylation of lysine 53 in intracellular NAMPT by SIRT1 predisposes
the protein to secretion by adipocytes and increases secreted extracellular NAMPT activity.
Adipose tissue-specific NAMPT knockout and knockin mice showed reciprocal changes in
circulating NAMPT levels which affected hypothalamic NAD+ and SIRT1 signaling as well
as physical activity. Finally, administration of a NAMPT-neutralizing antibody suppressed
NAMPT enzymatic activity by 90% for recombinant NAMPT in vitro and by 40% for
extracellular NAMPT in plasma and also decreased hypothalamic NAD+ production in vivo.
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It is clear that given its pleiotropic effects, NAMPT can exert other effects that promote
pulmonary vascular remodeling beyond inducing PASMC proliferation in a paracrine
manner. For instance, our results and the work of others suggest that NAMPT activity
directly promotes endothelial and smooth muscle cell proliferation12, 13. Our data from
Nampt+/− mice and from NAMPT loss of function studies in hPASMCs also suggest that
normal NAMPT levels are required to promote cell proliferation both in physiologic and
pathologic conditions. By regulating cellular NAD levels and the activity of NAD dependent
enzymes such as sirtuins and ADP-ribosyltransferases, NAMPT plays an important role in
the regulation of programmed cell death pathways. In models of acute inflammation
NAMPT activity prevents the apoptosis of neutrophils60. NAMPT also protects cells from
apoptosis by inhibiting the activity of p5361–63. SIRT3 has also been found to prevent loss of
mitochondrial membrane potential and cell death in response to hypoxia and staurosporine
treatment64. Current and future studies by our group are seeking to elucidate the molecular
mechanisms associated with increased proliferation and cell survival of PAECs and
PASMCs in the context of PAH. Finally, T and B lymphocytes and macrophages are present
Circulation. Author manuscript; available in PMC 2018 April 18.
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in increased numbers in and around the pulmonary arteries of patients with PAH and these
cells could be another source of NAMPT within the PAH lung microenvironment.65
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Our results show that NAMPT inhibition with FK866 has therapeutic effects in pre-clinical
models of PH by attenuating pulmonary vascular remodeling characterized by medial
hypertrophy and neointima formation. FK866 specifically inhibits NAMPT activity likely by
functioning as a substrate (NAM) mimetic which leads to a decrease is NAD synthesis.21
NAMPT inhibitors have been shown to have therapeutic effects in preclinical studies by
inhibiting cell proliferation and promoting apoptosis in cancer models21, inhibiting T-cell
proliferation and survival in autoimmune encephalomyelitis55, inhibiting inflammatory
cytokine production in collagen-induced arthritis66 and inducing neutrophil apoptosis in
LPS-induced acute lung injury60. NAMPT inhibitors have also been studied in phase I-II
human clinical trials in patients with cancer67–70. In these studies, the main dose limiting
toxicities included hematologic abnormalities (thrombocytopenia, leukopenia and anemia)
as well as several gastrointestinal symptoms such as nausea, vomiting, anorexia and
abdominal pain.67–70
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Our hemodynamic studies are limited by an indirect assessment of PA pressures via
measurement of RVSP and lack of a direct assessment of cardiac output or left ventricular
function. Further animal and human studies are needed to completely characterize the effects
of NAMPT inhibition on the pulmonary and systemic vasculatures as well as its effects on
right and left ventricular function. The results of our pre-clinical studies also highlight the
relative limitations of the existing experimental PH models. NAMPT inhibition had a much
more pronounced therapeutic effect in the monocrotaline than in the Sugen-hypoxia PH
model. This is consistent with the notion that the Sugen-hypoxia PH model more closely
mimics the severe pulmonary vascular remodeling and pulmonary hypertension associated
with human PAH, suggesting that this model is likely more suitable to test the translational
potential of novel therapeutic strategies for the disease.
In summary, we have demonstrated that NAMPT promotes pulmonary vascular remodeling
and contributes to PAH pathobiology. Most importantly, our results suggest that NAMPT is a
novel potential therapeutic target for PAH that should be explored in future preclinical and
clinical studies.
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Clinical Perspective
What is new?
•

Nicotinamide phosphoribosyltransferase (NAMPT), a pleiotropic protein with
extracellular proinflammatory cytokine-like activity and intracellular
enzymatic activity as a phosphoribosyltransferase, is upregulated in human
and experimental pulmonary hypertension and promotes pulmonary vascular
remodeling in vivo and in vitro.

What are the clinical implications?
•

Inhibition of NAMPT enzymatic activity is a potential novel therapeutic
strategy for pulmonary arterial hypertension.
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Figure 1. Plasma NAMPT levels, mRNA and protein levels of NAMPT in the lungs and PAECs
are up regulated in patients with PAH
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(A) Plasma NAMPT levels are higher in patients with PAH (n = 103) when compared to
non-PAH controls (n = 53); (B) NAMPT mRNA levels are upregulated in the lungs of the
patients with PAH (n = 4), compared to non-PAH controls (n = 4); (C–D) Representative
Western blotting images and β-actin-normalized quantification of protein demonstrate that
NAMPT expression is significantly increased in lungs from PAH patients when compared to
non-PAH controls; (E–F) Representative Western blotting images and β-actin-normalized
quantification of protein demonstrate that NAMPT protein levels were upregulated in
PAECs isolated from PAH patients (n = 3) when compared to non-PAH controls (n = 3).
Results are expressed as mean ± SEM. *, p < 0.05; ***, p < 0.001 versus control.
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Figure 2. NAMPT protein levels are significantly increased in lungs from three different rodent
models of pulmonary hypertension

(A) Representative Western blotting images and β-actin-normalized quantification of protein
demonstrate that NAMPT expression is significantly increased in mouse lungs after 4-week
10% hypoxia exposure. (B) Representative Western blotting images and β-actin-normalized
quantification of protein demonstrate that NAMPT expression is significantly increased in
the lungs from a rat model of PH mediated by monocrotaline. (C) Representative Western
blotting images and β-actin-normalized quantification of protein demonstrate that NAMPT
expression is significantly increased in the lungs from hypoxia plus sugen mediated PH in
rats. **,p<0.01 versus controls.
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Figure 3. Nampt+/− mice are protected against hypoxia-mediated pulmonary hypertension and
PASMCs isolated from Nampt+/− mice are less proliferative

When compared to WT controls, Nampt+/− mice exposed to hypoxia developed (A) less
severe elevations in RVSP, (B) less right ventricular hypertrophy (RV/(LV+S)) and lower
increases in ratios of wall area to total vessel area of pulmonary arteries less than 50 μm (C)
and 50–100 μm in diameter (D). (E) Representative pulmonary artery images in the lung
sections of control and Nampt+/− mice exposed to normoxia or hypoxia. BrdU proliferation
assays (F) and cell counting data (G) demonstrate that PASMCs isolated from Nampt+/−
mice are less proliferative compared to WT mice under either normoxia or hypoxia. Bar
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size: 20 μm. Results are expressed as mean ± SEM; n = 10 per group. *, p < 0.05; **, p <
0.01; ***, p < 0.001 versus hypoxia WT group.
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Figure 4. NAMPT promotes proliferation of PASMCs or PAECs in a paracrine and autocrine
manner

Author Manuscript

(A) PAECs isolated from PAH patients secret more NAMPT compared to non-PAH controls
(n=3 per group); (B) BrdU incorporation assays demonstrate that cell culture medium of
PAECs isolated from PAH patients stimulates more PASMC proliferation, and this effect can
be attenuated by the specific NAMPT inhibitor, FK866(10 μM) (ANOVA P < 0.05 for the
control to PAH comparison). Overexpressing NAMPT in hPAECs increases NAMPT
expression and secretion (C–E). NAMPT overexpression promotes cell proliferation and its
proliferative effect is attenuated by FK866 (10 μM) (F, ANOVA P < 0.05 for the vehicle to
NAMPT and NAMPT+FK-866 comparison). Overexpressing NAMPT in hPASMCs (G–H)
promotes cell proliferation and its proliferative effect is attenuated by FK866 (I, ANOVA P
< 0.05 for the control to NAMPT and NAMPT+FK-866 comparison). Cell culture medium
of PAECs overexpressing NAMPT stimulates more PASMC proliferation, and this effect is
attenuated by FK866 (10 μM) (J, ANOVA P < 0.05 for the vehicle to NAMPT and NAMPT
+FK-866 comparison). (K) recombinant NAMPT protein stimulates human PASMC
proliferation in a dose dependent manner and this effect is attenuated by FK866 (10 μM,
ANOVA P < 0.05 for the different NAMPT doses and NAMPT+FK-866 comparison).
Results are expressed as mean ± SEM. *, p < 0.05; **, p < 0.01; ***, P < 0.001 versus the
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pairwise comparison indicated by brackets. FBS or PDGF were used as positive controls for
BrdU proliferation assays as stated in the specific figures.
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Figure 5. NAMPT Enhances Store-Operated Calcium Entry (SOCE) in PASMCs

Incubation of hPASMCs with rNAMPT protein (20 μg/ml, 48 hrs) enhances cpA-mediated
store operated calcium entry (SOCE) (A), and increases ORAI2/STIM2 expression which is
attenuated by FK866 (10 μM) (B–E). Silencing of STIM2 or ORAI2 attenuates rNAMPTmediated hPASMC proliferation (F). Results are expressed as mean ± SEM, experiments
were repeated at least three times. *, p < 0.05; **, p < 0.01.
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Figure 6. NAMPT inhibition prevents monocrotaline-induced pulmonary hypertension in rats
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(A) Changes in RVSP. (B) Changes in RV/(LV+S). (C) Changes in ratios of wall area to total
vessel area of pulmonary arteries less than 50 μm in diameter in the lung sections of control
and FK866 treated (2.5mg/kg every 48 hours IP) groups with or without one dose of
monocrotaline (MCT, 60 mg/kg bw, SQ). (D) Changes in ratios of wall area to total vessel
area of pulmonary arteries 50–100 μm in diameter in the lung sections of control and FK866
treated groups with or without one dose of MCT (60 mg/kg bw, SQ). (E) Changes of RV
contractility index after FK866 treatment. The RV contractility index was calculated as
(dp/dt)max/instantaneous RV pressuremax, as demonstrated previously.27 (F) Representative
pulmonary artery images in the lung sections of control and FK866 treated (2.5mg/kg every
Circulation. Author manuscript; available in PMC 2018 April 18.
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48 hours IP) groups with or without one dose of MCT (60 mg/kg bw, SQ). Bar size: 20 μm.
Results are expressed as mean ± SEM; n = 6–8 per group. *, p < 0.05; ***, p < 0.001.
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Figure 7. NAMPT inhibition attenuates monocrotaline-induced pulmonary hypertension in rats
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(A) Changes in RVSP. (B) Changes in RV/(LV+S). (C) Changes in ratios of wall area to total
vessel area of pulmonary arteries less than 50 μm in diameter in the lung sections of control
and FK866 treated (2.5mg/kg every 48 hours IP) groups with or without one dose of
monocrotaline (MCT, 60 mg/kg bw, SQ). (D) Changes in ratios of wall area to total vessel
area of pulmonary arteries 50–100 μm in diameter in the lung sections of control and FK866
treated (2.5mg/kg every 48 hours IP) groups with or without one dose of MCT (60 mg/kg
bw, SQ). (E) Changes of RV contractility index after FK866 treatment. The RV contractility
index was calculated as (dp/dt)max/instantaneous RV pressuremax, as demonstrated
previously.27 (F) Representative pulmonary artery images in the lung sections of control and
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FK866 treated (2.5mg/kg every 48 hours IP) groups with or without one dose of MCT (60
mg/kg bw, SQ). Bar size: 20 μm. Results are expressed as mean ± SEM; n = 6–8 per group.
**, p < 0.01; ***, p < 0.001.
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Figure 8. NAMPT inhibition attenuates hypoxia plus sugen-mediated pulmonary hypertension in
rats

(A) Changes in RVSP. (B) Changes in RV/(LV+S). (C) Changes in ratios of wall area to total
vessel area of pulmonary arteries less than 50 μm in diameter in the lung sections of control
and FK866 treated (2.5mg/kg every 48 hours IP) groups; (D) Changes in ratios of wall area
to total vessel area of pulmonary arteries 50–100 μm in diameter in the lung sections of
control and FK866 treated (2.5mg/kg every 48 hours IP) groups; (E) Changes of RV
contractility index after FK866 treatment. The RV contractility index was calculated as
(dp/dt)max/instantaneous RV pressuremax, as demonstrated previously.27 (F) Representative
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pulmonary artery images in the lung sections of control and FK866 treated (2.5mg/kg every
48 hours IP) groups; (G) Percentage of occlusive PAs significantly decreases with FK866
therapy (2.5mg/kg every 48 hours IP). Bar size: 20 μm. Results are expressed as mean ±
SEM; n = 8–12 per group. *, p < 0.05; **, p < 0.01; ***, p < 0.001
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